Chemotherapy followed by letrozole sets standard for advanced, low-grade serous gynecologic carcinoma

MedicalXpress | avr. 13, 2026

Late-breaking results from the Phase III NRG GY019 trial indicate that letrozole monotherapy (L) did not demonstrate noninferiority to paclitaxel/carboplatin followed by letrozole (PC/L) for progression-free survival (PFS) in patients with newly diagnosed stage II-IV low-grade serous carcinoma of the ovary or peritoneum.